Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000545
Abstract: Liposomal irinotecan (irinotecan liposome injection, nal-IRI), a liposomal formulation of irinotecan, is designed for extended circulation relative to irinotecan and for exploiting discontinuous tumor vasculature for enhanced drug delivery to tumors. Following tumor deposition, nal-IRI… read more here.
Keywords: topotecan irinotecan; antitumor activity; iri; nal iri ... See more keywords